Riboflavin

Riboflavin

SCHEMBL1983532

Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@H](O)[C@H](O)[C@H](O)CO)c2cc1C.[NaH]

nearest known ligand 0.98

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.98
KMT2A Q03164 7/20 0.98
USP2 O75604 4/20 0.98
KDM4E B2RXH2 4/20 0.98
HAT1 O14929 4/20 0.98
RBBP7 Q16576 4/20 0.98
HTT P42858 4/20 0.98
RECQL P46063 3/20 0.98
CASP7 P55210 3/20 0.98
MAPT P10636 3/20 0.98
CASP1 P29466 2/20 0.98
BRCA1 P38398 2/20 0.98
HSD17B10 Q99714 2/20 0.98
TST Q16762 2/20 0.98
TDP1 Q9NUW8 2/20 0.98
ALDH1A1 P00352 2/20 0.98
LMNA P02545 1/20 0.98
HBB P68871 1/20 0.98
CYP1A2 P05177 1/20 0.98
CYP3A4 P08684 1/20 0.98

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Riboflavin SCHEMBL4380877 1.00 MEN1 (0.98) MEN1KMT2AUSP2KDM4EHAT1
Riboflavin SCHEMBL28003822 0.99 MEN1 (0.96) MEN1KMT2AUSP2KDM4EHAT1
Riboflavin SCHEMBL246757 0.99 MEN1 (0.96) MEN1KMT2AUSP2KDM4EHAT1
Riboflavin SCHEMBL1064647 0.99 MEN1 (0.96) MEN1KMT2AUSP2KDM4EHAT1
Riboflavin SCHEMBL13373926 0.99 MEN1 (1.00) MEN1KMT2AUSP2KDM4EHAT1
Riboflavin SCHEMBL7707 0.99 MEN1 (1.00) MEN1KMT2AUSP2KDM4EHAT1
Riboflavin SCHEMBL5899262 0.99 MEN1 (1.00) MEN1KMT2AUSP2KDM4EHAT1
Riboflavin SCHEMBL7706 0.99 MEN1 (1.00) MEN1KMT2AUSP2KDM4EHAT1
Riboflavin SCHEMBL14146654 0.99 MEN1 (1.00) MEN1KMT2AUSP2KDM4EHAT1
Riboflavin SCHEMBL12979917 0.99 MEN1 (1.00) MEN1KMT2AUSP2KDM4EHAT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113795565-B Tracer composition 切尔西科技有限公司 2025-04-08 CN claimed
CN-119751771-A Photopolymer holographic recording medium, grating, preparation method and equipment thereof 珠海莫界科技有限公司 2025-04-04 CN claimed
CN-118576619-B A composition containing vitamins and minerals 深圳奥萨制药有限公司 2024-11-22 CN claimed
CN-118931526-A CeO-based2Enhanced fluorescent probe and application thereof in detection of sulfide ions or sulfate reducing bacteria 华中科技大学 2024-11-12 CN claimed
CN-118845988-A Composite preparation for weight reduction after operation and preparation method thereof 四川大学华西医院 2024-10-29 CN claimed
CN-118576619-A A composition containing vitamins and minerals 深圳奥萨制药有限公司 2024-09-03 CN claimed
CN-116685297-A Tooth surface coloring composition 爱欧白欧有限公司 2023-09-01 CN claimed
CN-114314574-A Riboflavin sodium phosphate-assisted large-size graphene water-phase preparation method 复旦大学 2022-04-12 CN claimed
CN-104490902-B A kind of composite vitamin for injection freeze drying powder injection composition and preparation method thereof 李迪 2018-04-27 CN claimed
CN-104490903-B A kind of Compound vitamine injection pharmaceutical composition and preparation method thereof 王大光 2017-11-21 CN claimed
CN-107286194-A A kind of riboflavin phosphate process for producing sodium 山西集翔生物工程有限公司 2017-10-24 CN claimed
CN-104490901-B A kind of Compound vitamine injection pharmaceutical composition and preparation method 王大光 2017-06-27 CN claimed
CN-104523714-B A kind of Compound vitamine injection pharmaceutical composition and preparation method 李迪 2017-06-27 CN claimed
US-8182850-B2 Mixture of iron and copper salts masking metallic taste BAYER CONSUMER CARE AG (CH) 2012-05-22 US claimed
CN-121628874-B EC riboflavin kinase mutant and application thereof 深圳希吉亚生物技术有限公司 2026-05-15 CN disclosed
US-20260076399-A1 READY-TO-USE PARENTERAL NUTRITION FORMULATION BAXTER INT (US) 2026-03-19 US disclosed
WO-2026007754-A1 CEO2-BASED ENHANCED FLUORESCENT PROBE AND USE THEREOF IN DETECTION OF SULFUR IONS OR SULFATE-REDUCING BACTERIA 华中科技大学 2026-01-08 WO disclosed
EP-0199524-A2 Platinum tramine antitumor agents ENGELHARD CORPORATION (US) 1986-10-29 EP disclosed
EP-0191624-A2 Gold-purine antitumor agents ENGELHARD CORPORATION (US) 1986-08-20 EP disclosed
EP-0174114-A1 Platinum complexes of ascorbic acid and ascorbic acid analogs ENGELHARD CORPORATION (US) 1986-03-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260076399-A1 READY-TO-USE PARENTERAL NUTRITION FORMULATION PROC, MMAB, SLC5A6 MEN1 61/4885KMT2A 2892/4885USP2 1198/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.